OBJECTIVE: To identify prognostic indicators that influence post-recurrence survival following radical cystectomy for bladder cancer. PATIENTS AND METHODS: In all, 2029 patients with bladder cancer underwent radical cystectomy with intent to cure between 1971 and 2005 at our institution. Of these, 447 patients (22%) developed non-urinary tract recurrence and were chosen for further analysis. Clinicopathological characteristics were analysed by univariate and multivariate analysis to identify factors prognostic for post-recurrence survival. RESULTS: Median time to recurrence was 13.21 months and median post-recurrence overall survival was 5.59 months. Pathological stage (P < 0.001), intravesical therapy (P= 0.035), tumour upstaging (P < 0.001), lymph node density (P < 0.001) and recurrence site (P= 0.017) were associated with time to recurrence. Age (P= 0.042), type of urinary diversion (P < 0.014), surgical margin status (P= 0.049), pathological stage (P < 0.001), lymph node density (P < 0.001), time to recurrence (P < 0.001), recurrence site (P < 0.001) and post-recurrence chemotherapy administration (P < 0.001) were univariately prognostic for post-recurrence overall survival. Multivariate analysis confirmed the associations of pathological stage, type of urinary diversion, lymph node density, time to recurrence after cystectomy, site of recurrence and post-recurrence chemotherapy administration with outcome following bladder cancer recurrence. Median post-recurrence survival with either local or distant recurrence was 7.95 months and 5.95 months, respectively, whereas patients with both local and distant recurrences had median post-recurrence survival of 3.98 months. CONCLUSIONS: Bladder cancer recurrence forebodes poor prognosis, with 6 months' median survival following recurrence. Advanced pathological stage, positive surgical margins, high lymph node density and early recurrence portends poorer outcome. Although patients with local recurrence have a slightly better prognosis, those with disease recurrence at local and distant sites perform very poorly; nearly 97% of all patients with recurrence eventually succumb to the disease. Chemotherapy administration following recurrence may improve survival, although further studies are needed to exclude selection bias.
OBJECTIVE: To identify prognostic indicators that influence post-recurrence survival following radical cystectomy for bladder cancer. PATIENTS AND METHODS: In all, 2029 patients with bladder cancer underwent radical cystectomy with intent to cure between 1971 and 2005 at our institution. Of these, 447 patients (22%) developed non-urinary tract recurrence and were chosen for further analysis. Clinicopathological characteristics were analysed by univariate and multivariate analysis to identify factors prognostic for post-recurrence survival. RESULTS: Median time to recurrence was 13.21 months and median post-recurrence overall survival was 5.59 months. Pathological stage (P < 0.001), intravesical therapy (P= 0.035), tumour upstaging (P < 0.001), lymph node density (P < 0.001) and recurrence site (P= 0.017) were associated with time to recurrence. Age (P= 0.042), type of urinary diversion (P < 0.014), surgical margin status (P= 0.049), pathological stage (P < 0.001), lymph node density (P < 0.001), time to recurrence (P < 0.001), recurrence site (P < 0.001) and post-recurrence chemotherapy administration (P < 0.001) were univariately prognostic for post-recurrence overall survival. Multivariate analysis confirmed the associations of pathological stage, type of urinary diversion, lymph node density, time to recurrence after cystectomy, site of recurrence and post-recurrence chemotherapy administration with outcome following bladder cancer recurrence. Median post-recurrence survival with either local or distant recurrence was 7.95 months and 5.95 months, respectively, whereas patients with both local and distant recurrences had median post-recurrence survival of 3.98 months. CONCLUSIONS:Bladder cancer recurrence forebodes poor prognosis, with 6 months' median survival following recurrence. Advanced pathological stage, positive surgical margins, high lymph node density and early recurrence portends poorer outcome. Although patients with local recurrence have a slightly better prognosis, those with disease recurrence at local and distant sites perform very poorly; nearly 97% of all patients with recurrence eventually succumb to the disease. Chemotherapy administration following recurrence may improve survival, although further studies are needed to exclude selection bias.
Authors: Michael Rink; Daniel Sjoberg; Evi Comploj; Vitaly Margulis; Evanguelos Xylinas; Richard K Lee; Jens Hansen; Eugene K Cha; Jay D Raman; Mesut Remzi; Karim Bensalah; Giacomo Novara; Surena F Matin; Felix K Chun; Eiji Kikuchi; Wassim Kassouf; Juan I Martinez-Salamanca; Yair Lotan; Christian Seitz; Armin Pycha; Richard Zigeuner; Pierre I Karakiewicz; Douglas S Scherr; Andrew J Vickers; Shahrokh F Shariat Journal: Ann Surg Oncol Date: 2012-07-18 Impact factor: 5.344
Authors: Andrew D Chung; Nicola Schieda; Trevor A Flood; Ilias Cagiannos; Kien T Mai; Shawn Malone; Christopher Morash; Shaheed W Hakim; Rodney H Breau Journal: Can Urol Assoc J Date: 2017-01-12 Impact factor: 1.862
Authors: Zhoobin H Bateni; Shane M Pearce; Daniel Zainfeld; Leslie Ballas; Hooman Djaladat; Anne K Schuckman; Siamak Daneshmand Journal: Eur Urol Oncol Date: 2018-12-19
Authors: Vivek Venkatramani; Isildinha M Reis; Erik P Castle; Mark L Gonzalgo; Michael E Woods; Robert S Svatek; Alon Z Weizer; Badrinath R Konety; Mathew Tollefson; Tracey L Krupski; Norm D Smith; Ahmad Shabsigh; Daniel A Barocas; Marcus L Quek; Atreya Dash; Adam S Kibel; Raj S Pruthi; Jeffrey Scott Montgomery; Christopher J Weight; David S Sharp; Sam S Chang; Michael S Cookson; Gopal N Gupta; Alex Gorbonos; Edward M Uchio; Eila Skinner; Nachiketh Soodana-Prakash; Maria F Becerra; Sanjaya Swain; Kerri Kendrick; Joseph A Smith; Ian M Thompson; Dipen J Parekh Journal: J Urol Date: 2019-09-24 Impact factor: 7.450
Authors: Guru Sonpavde; Gregory R Pond; Ronan Fougeray; Toni K Choueiri; Angela Q Qu; David J Vaughn; Guenter Niegisch; Peter Albers; Nicholas D James; Yu-Ning Wong; Yoo-Joung Ko; Srikala S Sridhar; Matthew D Galsky; Daniel P Petrylak; Ulka N Vaishampayan; Awais Khan; Nicholas J Vogelzang; Tomasz M Beer; Walter M Stadler; Peter H O'Donnell; Cora N Sternberg; Jonathan E Rosenberg; Joaquim Bellmunt Journal: Eur Urol Date: 2012-11-26 Impact factor: 20.096